The company claims that in the trial, the activity of PA401 was benchmarked against other relevant treatment modalities including the PDE4 inhibitor roflumilast and the CXCR2 antagonist SCH527123.
ProtAffin CEO Jason Slingsby they are delighted to announce strong, differentiated efficacy data for our lead product PA401 in preclinical models relevant to COPD.
“We look forward to progressing PA401 through preclinical development in 2010 and 2011 and to starting Phase 1 trials early in 2012. Given the unique properties of PA401 in preclinical models of COPD, PA401 may represent a new treatment paradigm for patients with COPD,” Slingsby said.